Life Sciences

  • February 23, 2026

    CBP Clears Redesigned Tourniquet Imports After IP Ban

    U.S. Customs and Border Protection has found that a modified version of a tourniquet made by a Chinese company isn't subject to an import ban issued by the U.S. International Trade Commission after finding that earlier imports infringed a patent.

  • February 23, 2026

    Corcept Mischaracterized Drug Approval Odds, Investor Says

    Pharmaceutical company Corcept Therapeutics Inc. faces a proposed investor class action alleging it overstated approval prospects for a Cushing's syndrome drug candidate, hurting investors when its trading prices halved after it disclosed the U.S. Food and Drug Administration wouldn't accept the approval bid.

  • February 23, 2026

    Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit

    A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.

  • February 23, 2026

    Justices Want Natera's Take On CareDx's False Ad Petition

    The U.S. Supreme Court on Monday asked for Natera's position on a petition from rival CareDx asking the high court to review a Third Circuit decision that erased a $45 million jury award stemming from CareDx's false advertising claims.

  • February 23, 2026

    Asthma Biotech Generate Biomedicines Eyes $400M IPO

    Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.

  • February 23, 2026

    Life Sciences Group Of The Year: Ropes & Gray

    Ropes & Gray LLP guided Gilgamesh Pharmaceuticals in a potentially $1.2 billion deal with AbbVie and advised Novo Nordisk in eight licensing and mergers and acquisitions transactions for novel obesity and metabolic disease treatments, earning the firm a spot among the 2025 Law360 Life Sciences Group of the Year.

  • February 23, 2026

    Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told

    A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with "the same active ingredient" as weight loss drugs Ozempic and Wegovy despite containing other key ingredients, according to a suit filed in Illinois federal court. 

  • February 23, 2026

    Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

    Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share, reflecting an implied equity value of $7.8 billion.

  • February 20, 2026

    BioNTech Says Moderna's New COVID Vax Infringes Its IP

    BioNTech has launched a new patent infringement suit against Moderna, claiming that the rival's newer COVID-19 vaccine exploits BioNTech's "streamlined, domain-based" vaccine technology, according to a complaint filed in Delaware federal court.

  • February 20, 2026

    Dallas Jury Finds Ex-NFL Player Ran $328M Medicare Scheme

    A federal jury in Dallas has found that former NFL player and Texas laboratory owner Keith Gray orchestrated a $328 million fraud scheme involving billing for cardiovascular genetic testing, federal prosecutors said Thursday.

  • February 20, 2026

    Fertility Doctors Beat Patient's Embryo Loss Case

    A Connecticut woman waited too long to sue her fertility doctors over the loss of her frozen embryos after treatments in 2005 and 2006, a state court judge ruled Thursday, granting judgment to the doctors.

  • February 20, 2026

    Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP

    The Federal Circuit on Friday saved Regenxbio and the University of Pennsylvania's gene therapy patent, finding that splicing together genes from different organisms results in a molecule that is "markedly different from anything occurring in nature," rendering the therapy patent eligible. 

  • February 20, 2026

    Merck Wants Out Of Ex-Workers' Wage, ADA Suit

    Merck urged a North Carolina federal court on Friday to dismiss a former manufacturing facility employee's proposed class and collective action, arguing federal wage law bars his state overtime claim and that he failed to link his firing to sleep apnea.

  • February 20, 2026

    Chinese Chemical Imports Evading Duties, Commerce Says

    The U.S. Department of Commerce determined Friday that Chinese imports of a water treatment chemical into the U.S. are skirting antidumping and countervailing duties against such products after a U.S. company accused the countrywide industry of making misleading "minor" alterations.

  • February 20, 2026

    Beasley Allen Can't Pause NJ Talc DQ Order, Judge Rules

    The Beasley Allen Law Firm can't delay an order disqualifying it from representing hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder while it seeks review from the New Jersey Supreme Court, a state judge ruled on Friday.

  • February 20, 2026

    Judge Says Texas Can't Enforce Optometry Anti-Steering Law

    A Texas federal judge on Friday blocked the state from enforcing an anti-steering law that banned managed care plans from telling insureds about optometrists who offer cheaper options, saying that the law violated protected commercial speech. 

  • February 20, 2026

    US Hits Pill Capsules From 4 Countries With Duty Orders

    The U.S. Department of Commerce hit empty pill capsules from China, India, Brazil and Vietnam imported into the U.S. with antidumping and countervailing duty orders, with some of the rates stretching higher than 77%.

  • February 20, 2026

    Taxation With Representation: Freshfields, Simpson Thacher

    In this week's Taxation With Representation, science and technology company Danaher Corp. acquires medical technology company Masimo Corp., Covetrus merges with a unit of fellow animal health technology company Cencora, and private equity firm Leonard Green & Partners LP buys outstanding Mister Car Wash Inc. shares not already owned by LGP affiliates.

  • February 19, 2026

    Judge Denies Mylan And Aurobindo's Bid To Escape Trial

    A Connecticut federal judge has once again rejected generic-drug makers' bid to escape a multistate lawsuit accusing them of engaging in an overarching antitrust conspiracy, saying the evidence supports the need for a jury trial on whether the companies colluded to fix prices and divvy up markets for dozens of generic drugs.

  • February 19, 2026

    Texas Suit Says Sanofi Paid Kickbacks For Prescriptions

    Texas Attorney General Ken Paxton sued Sanofi-Aventis US LLC in state court Thursday, accusing the pharmaceutical company of paying kickbacks to providers so they would prescribe Sanofi's drugs.

  • February 19, 2026

    Justices Urged To Bar Passive Infringement For Skinny Labels

    The Federal Circuit cleared the path for branded-drug makers to claim a rival induced infringement of a patent without taking any active steps to do so, Hikma told the U.S. Supreme Court in a case over so-called skinny labels.

  • February 19, 2026

    Judge Affirms Literal Infringement In Ravgen's $57M Jury Win

    A Texas federal judge has upheld a jury's finding that genetic testing company Natera Inc. committed literal infringement of a patent held by Ravgen Inc., but said Ravgen's expert testimony wasn't enough to support the jury's finding of infringement under the doctrine of equivalents.

  • February 19, 2026

    Red State AGs Back La. Bid To Halt Eased Abortion Pill Rules

    A coalition of 21 Republican state attorneys general, led by Nebraska, urged a federal judge to grant Louisiana's bid to block the U.S. Food and Drug Administration's 2023 rules easing access to the abortion drug mifepristone, arguing that the policy undermines states' authority to enforce their own abortion laws and imposes a "pocketbook injury" on states.

  • February 19, 2026

    She Has A Point: Dechert's Kassie Helm

    Kassie Helm, co-chair of Dechert LLP's global intellectual property group and head of its IP litigation group, is "unquestionably one of the leading lights of her generation," according to Morrison Foerster LLP partner Daralyn Durie, who praised Helm for her work as opposing counsel in a new series celebrating women litigators.

  • February 19, 2026

    Squires Accepts 8 PTAB Cases, Walks Back 7 Merits Referrals

    A bulk summary order from U.S. Patent and Trademark Office Director John Squires granted eight petitions for America Invents Act patent challenges while denying 14 others, including seven that he had previously accepted for merits-based review.

Expert Analysis

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

  • Unpacking Dormant Commerce Clause Cannabis Circuit Split

    Author Photo

    Federal courts have reached differing conclusions as to whether state-legal cannabis is subject to the dormant commerce clause, with four opinions across three circuit courts in the last year demonstrating the continued salience of the dormant commerce clause debate to the nation's cannabis industry, regulators and policymakers, say attorneys at Perkins Coie.

  • Opinion

    CFIUS Must Adapt To Current Foreign Investment Realities

    Author Photo

    To continue protecting the U.S.’ long-term strategic and economic interests, the Committee on Foreign Investment in the United States should implement practical enhancements that leverage technology, expertise and clear communication, and enable it to keep pace with evolving demands, says attorney Sohan Dasgupta.

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.